NCT07067450 2025-07-16
Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma
Sichuan University
Phase NA Not yet recruiting
Clinical Trials
19 trialsNCT04548440 2025-06-12
Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients
Sun Yat-sen University
Phase 2 Completed
NCT05357846 2025-06-12
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
Sun Yat-sen University
Phase 3 Recruiting
NCT04212598 2024-12-10
The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer
Wuhan University
Phase 2 Completed
NCT06709417 2024-11-29
A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)
Shanghai Chest Hospital
Phase 2 Recruiting
NCT03985046 2024-11-07
Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC
Fudan University
Phase 2 Completed
NCT05495152 2024-10-02
Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma
Henan Cancer Hospital
Phase 3 Recruiting
NCT06463834 2024-06-18
A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
Fujian Cancer Hospital
Phase 2 Recruiting
NCT06190639 2024-01-05
A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC
Zhejiang Cancer Hospital
Phase 2 Recruiting
NCT06152978 2023-12-01
A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma
Fudan University
Phase 2 Not yet recruiting
NCT03748134 2023-10-24
Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT05244798 2022-10-25
Sintilimab Plus NCT or NCRT Versus NCRT for ESCC
Sichuan Cancer Hospital and Research Institute
Phase 3 Not yet recruiting
NCT03946969 2022-07-19
Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT04625543 2022-04-26
Neoadjuvant Immunotherapy to ESCC
Qilu Hospital of Shandong University
Phase 2 Withdrawn
NCT05174325 2021-12-30
Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT04813406 2021-03-24
Study of Anlotinib Plus Sintilimab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
Henan Provincial People's Hospital
Phase NA Unknown
NCT03116152 2021-02-03
Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2 Completed
NCT04602013 2020-10-26
Sintilimab Injection Combined With Concurrent CCRT in Locally Advanced Esophageal Squamous Cell Carcinoma
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT03940001 2019-09-09
A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer
Zhejiang Cancer Hospital
Phase EARLY_PHASE1 Unknown